Please ensure Javascript is enabled for purposes of website accessibility

FDA Shines a Spotlight on Asbestos Testing for Talc Products

By Cory Renauer – Feb 4, 2020 at 4:14PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A rare public meeting to discuss the testing of personal care products for asbestos was informative and disturbing.

Scrutiny of talc-based cosmetics and personal care products such as eye shadow and Johnson & Johnson's (JNJ 1.04%) baby powder has been on the rise in light of cases of cancer associated with their long-term use. On Tuesday, the Food and Drug Administration held its first public meeting in decades on the subject of asbestos testing, and the agency's recommendations weren't what manufacturers of those talc-based products wanted to hear.

Consumers hoping the FDA will step in to guarantee the safety of the products they apply to their skin should know the agency doesn't have a lot of control when it comes to cosmetics. One thing the agency can do, though, is promulgate a set of best practices -- recommendations about what companies like Johnson & Johnson should do in the interest of public safety. 

Person holding dice that spell FDA.

Image source: Getty Images.

Elongate mineral particles

One of the big takeaways from the FDA's recommendations was the agency's insistence on a new standard for talc testing that includes all elongate mineral particles (EMPs) that are at least three times as long as they are wide. More data would be helpful, but it appears that an elongated silicate crystal doesn't need to meet all the criteria that define asbestos for exposure to it to increase a person's risk of developing cancer.

Before the government adds to the list of potential carcinogens that cosmetics manufacturers should screen for, it needs to set a standard threshold for acceptable EMP concentration. At the moment, some laboratories don't flag anything with asbestos concentrations of less than 1% even though it's extremely unusual to find contamination at concentrations of 0.1% or higher.

Cory Renauer owns shares of Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$166.66 (1.04%) $1.72

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.